Arena Pharmaceuticals, Inc. announced that effective February 12, 2021, board of directors (the Board) increased the size of the Board from nine directors to ten directors and appointed Nawal Ouzren to serve as director until her successor is duly elected and qualified, or until her earlier death, resignation or removal. The Board also appointed Ms. Ouzren to its Compensation Committee. Ms. Ouzren, 42, brings 20 years of leadership and expertise across a range of areas, including clinical development, operations, manufacturing, quality, and commercialization. She currently serves as Chief Executive Officer and Member of the Board at Sensorion SAS.